The trial, sponsored by Peking University, aims to evaluate the safety and tolerability of PD-1 knockout engineered T cells in patients with stage IV muscle-invasive bladder cancer. Given the increasing focus on immunotherapy and the potential for PD-1 inhibition to enhance anti-tumor responses, this asset could represent a significant advancement in the treatment of advanced bladder cancer. However, the trial has been withdrawn due to lack of funding, which raises concerns about the viability of further development without securing financial backing. The competitive landscape includes other PD-1/PD-L1 inhibitors currently in various stages of development, necessitating a thorough diligence process to assess market positioning and potential partnerships.